TRISCEND II Pivotal Trial 2020-05 CONTINUED ACCESS STUDY
Research payments
$2,545,771
Through program year 2025, $2,545,771 in research payments was reported against TRISCEND II Pivotal Trial 2020-05 CONTINUED ACCESS STUDY, across 276 payments, paid by Edwards Lifesciences Corporation.
- Paid by
- Edwards Lifesciences Corporation
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
3 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | Research | $481,821 | 110 |
| 2024 | Research | $1,933,993 | 154 |
| 2023 | Research | $129,957 | 12 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Paul Grayburn Plano, TX Named on 17 payments
- Robert Kipperman Oklahoma City, OK Named on 11 payments
- George Petrossian Philadelphia, PA Named on 8 payments
- Pradeep Yadav Atlanta, GA Named on 8 payments
- Susheel Kodali New York, NY Named on 8 payments
- Charles Davidson Chicago, IL Named on 6 payments
- Ming Zhang Seattle, WA Named on 6 payments
- Firas Zahr Portland, OR Named on 6 payments
- Abhijeet Dhoble Houston, TX Named on 5 payments
- Pinak Shah Boston, MA Named on 5 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.